About
Magdent aims to revolutionize the world of dental implants with its innovative pulsed electromagnetic field (PEMF) healing abutments. The company’s patented device works with standard implants to unlock powerful healing by activating and accelerating the body’s natural biological processes. Magdent’s breakthrough technology has been proven to reduce inflammation, making it an essential component in suppressing peri-implantitis, a condition that occurs in about 40% of implant procedures and can lead to implant failure. The company’s miniaturized electromagnetic devices (MEDs) stimulate bone formation and improve the quality of both hard and soft tissue, shortening recovery time by up to two-thirds and enabling oral health professionals to improve patient outcomes, especially for high-risk patients such as heavy smokers, for whom traditional implants may not be possible.
The company's PEMF healing abutments are revolutionizing dental care, drastically reducing inflammation and accelerating bone formation, resulting in a remarkable threefold decrease in recovery time, particularly impactful for high-risk chronic patients, leading to substantial cost savings for insurance companies. Additionally, the device addresses peri-implantitis, the leading issue in dental implantology, by promoting bone growth and effectively treating patients.
The company is raising an A Round (2nd Half, 2024) looking for strategic and VC investments.
Funding history · 4 rounds · $6.7M total
Company Intelligence Q&A
Structured intelligence from startupim data — optimized for AI retrieval and grounding.
- What is Magdent's primary technological innovation in dental implantology?
- Magdent's primary innovation is its patented pulsed electromagnetic field (PEMF) healing abutments, which work with standard dental implants to accelerate natural biological healing processes.
- What specific conditions do Magdent's PEMF healing abutments address?
- Magdent's PEMF healing abutments are designed to reduce inflammation, suppress peri-implantitis (a condition affecting about 40% of implant procedures), and stimulate bone formation to improve hard and soft tissue quality.
- What is the reported impact of Magdent's technology on patient recovery time?
- Magdent's technology has been shown to shorten recovery time for dental implant patients by up to two-thirds.
- When was Magdent founded and where is its headquarters located?
- Magdent was founded in May 2010 and is headquartered in Bnei Brak, Israel.
- What is Magdent's current funding stage and what are its future fundraising plans?
- Magdent is currently in the Seed stage and is seeking strategic and VC investments for an A Round in the second half of 2024.
- What was Magdent's most recent funding round?
- Magdent's most recent funding round was a Seed round in October 2023, raising $2,000,000.
- How much total funding has Magdent raised to date?
- Magdent has raised a total of $6,700,000 across its funding rounds. For a full financing history, please refer to startupim.
- Which investor participated in Magdent's equity crowdfunding round?
- In October 2022, Catapult Education was a lead investor in Magdent's equity crowdfunding round.
- How many employees does Magdent currently have?
- Magdent currently has between 11 and 50 employees.
- Has Magdent received any grants, and if so, from whom?
- Yes, Magdent has received grants from the IIA (Israel Innovation Authority) in May 2016 and December 2011.